UY39724A - Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a - Google Patents

Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a

Info

Publication number
UY39724A
UY39724A UY0001039724A UY39724A UY39724A UY 39724 A UY39724 A UY 39724A UY 0001039724 A UY0001039724 A UY 0001039724A UY 39724 A UY39724 A UY 39724A UY 39724 A UY39724 A UY 39724A
Authority
UY
Uruguay
Prior art keywords
combination
antibody against
treating
malignant neoplasm
prolgolimab
Prior art date
Application number
UY0001039724A
Other languages
English (en)
Inventor
Dmitry Valentinovich Morozov
Mariia Stanislavovna Shustova
Sergei Nikolaevich Fogt
Fedor Borisovich Kryukov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021109765A external-priority patent/RU2787457C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39724A publication Critical patent/UY39724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

La presente invención se refiere al uso del anticuerpo contra PD-1, en particular prolgolimab, en combinación con al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna, y al uso del anticuerpo contra PD-1 prolgolimab en combinación con el anticuerpo contra VEGF, en particular bevacizumab, y al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna.
UY0001039724A 2021-04-08 2022-04-08 Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a UY39724A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021109765A RU2787457C2 (ru) 2021-04-08 Способ лечения злокачественного новообразования с использованием комбинации антитела к pd-1 и химиотерапевтического агента

Publications (1)

Publication Number Publication Date
UY39724A true UY39724A (es) 2022-10-31

Family

ID=83546621

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039724A UY39724A (es) 2021-04-08 2022-04-08 Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a

Country Status (9)

Country Link
EP (1) EP4319736A1 (es)
CN (1) CN117500493A (es)
AR (1) AR125322A1 (es)
BR (1) BR112023020856A2 (es)
CO (1) CO2023013510A2 (es)
EC (1) ECSP23076237A (es)
TW (1) TW202304511A (es)
UY (1) UY39724A (es)
WO (1) WO2022216184A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609957A2 (pt) * 2005-05-12 2010-05-11 Pfizer uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
CA3133821A1 (en) * 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody

Also Published As

Publication number Publication date
CO2023013510A2 (es) 2023-11-10
ECSP23076237A (es) 2024-01-31
TW202304511A (zh) 2023-02-01
WO2022216184A1 (en) 2022-10-13
EP4319736A1 (en) 2024-02-14
BR112023020856A2 (pt) 2024-02-06
AR125322A1 (es) 2023-07-05
CN117500493A (zh) 2024-02-02

Similar Documents

Publication Publication Date Title
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CO2017002081A2 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CL2017003458A1 (es) Metodos para tratar malignidad hematoligica usando terapia de combinacion del inhibidor de nanoparticulas mtor.
UA116095C2 (uk) Застосування пертузумабу, трастузумабу і хіміотерапії на основі карбоплатину для неоад'ювантного лікування her2-позитивного раку молочної залози ранньої стадії у пацієнта
SG10201906471PA (en) Treatment of cancer with anti-lap monoclonal antibodies
CL2021001366A1 (es) Anticuerpos humanizados contra c-kit
PE20180454A1 (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
PE20060461A1 (es) Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino
TR201907240T4 (tr) Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi.
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
UY38360A (es) Métodos de tratamiento del cáncer
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
BR112017028287A2 (pt) Combinação do inibidor hdac e anticorpido anti-pd- l1 para o tratamento do câncer
UY39724A (es) Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a
ECSP19083967A (es) Compuestos antitumorales
BR112021022784A2 (pt) Composições e métodos para tratamento do câncer
CL2017002275A1 (es) Cepas bacterianas productoras de histamina y su uso en el cáncer
CL2023000741A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos.
CL2023003100A1 (es) Anticuerpo biespecífico anti–cldn4/anti–cd137
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
WO2016196373A8 (en) Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
CR20140211A (es) Terapia de combinación para cáncer de ovario
BR112023004830A2 (pt) Métodos para tratamento de mieloma múltiplo
MX2020006368A (es) Uso de tratamiento combinado de anticuerpo pd-1 y apatinib para tratar cancer de mama triple negativo.